In the era of personalized cancer therapy, patients with TNBC remain at considerably higher risk of relapse and death than patients with other breast cancer subtypes, due to the aggressive nature of TNBC and the lack of newer targeted therapies for the disease. (sciencedaily.com)
Dr. Martinez - Agosto noted, «Looking at the functionality of these genes and their effect on the immune response has great potential for accelerating the development of new targeted therapies.» (sciencedaily.com)
«It contrasts so much with what you hear in cancer research: doctors developing new targeted therapy that costs $ 800 a month, and it works a little bit — but only for certain kinds of patients with certain kinds of tumors. (health.com)